In the phase 3 SLIMMER trial published in The Lancet Diabetes & Endocrinology last year, ecnoglutide achieved weight loss of 15.1% at 48 weeks, with no evidence of a plateauing of effect, along with improvements in waist circumference, blood pressure, lipid profile, HbA1c, fasting glucose, and insulin levels
External resources PubMed: Ipamorelin, the first selective growth hormone secretagogue PMC: Growth hormone secretagogues in body composition management In case I do not see you, good afternoon, good evening, and good night
GLP-1 and Inflammation in Endometriosis One of the most compelling reasons GLP-1 medications are being discussed in endometriosis is their effect on systemic inflammation and immune signaling
L.MilnerT
If you reach 4 mg and are losing 2 pounds per week consistently with minimal side effects, staying at 4 mg is a perfectly valid choice
Who Cannot Take Weight Loss Injections: Contraindications and Safety Weight loss injections, such as semaglutide (Wegovy) and liraglutide (Saxenda), are increasingly prescribed for obesity management in the UK